☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
HER2-
Celltrion and MSD Report Results of First-Line Triplet Regimen P-I/II PANTHERA trial in Patients with HER2-Positive Advanced Gastr...
May 27, 2020
Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metast...
May 27, 2019
Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer
January 3, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.